(All figures are presented in U.S. Dollars)
Highest single-quarter revenue in the Company's history with total revenue of $13.4 million in Q2 2025Adjusted EBITDA1 in Q2 2025 was $7.6 million, an increase of 148% over Q2 2024Epuris sales volumes grew 14% in the quarter compared to Q2 2024NatrobaTM sales were $7.8 million during the quarter, a sequential increase of 16% over Q1 2025Strong cash generation with $6.0 million cash from operations in Q2 2025$15.0 million debt repayment and share repurchases of $2.1 million during Q2 2025$7.0 million debt repayment subsequent to Q2 2025The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.